ASA404 Vascular Disrupting Agent for Solid Tumours

 

Key Data:

Drug (brand/generic)
ASA404
Company/licensee
Antisoma/Novartis
Therapy class
VDA
Product description
Small molecule drug designed to destroy tumour blood supply
Current indication
NSCLC
Market sector
Oncology
Development status
Phase II

Return to Project



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development